EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions

Christopher C Dvorak, Elie Haddad, Jennifer Heimall, Elizabeth Dunn, Rebecca H Buckley, Donald B Kohn, Morton J Cowan, Sung-Yun Pai, Linda M Griffith, Geoffrey D E Cuvelier, Hesham Eissa, Ami J Shah und 7 weitere

Journal of Allergy and Clinical Immunology · 2023-02 · 151 (2) · 539-546

DOI: 10.1016/j.jaci.2022.10.022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-02. Verfasst von Christopher C Dvorak und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, Calif. Electronic …. Hauptthemen laut MEDLINE: Severe Combined Immunodeficiency, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe combined immunodeficiency (SCID) results from defects in the differentiation of hematopoietic stem cells into mature T lymphocytes, with additional lymphoid lineages affected in particular genotypes. In 2014, the Primary Immune Deficiency Treatment Consortium published criteria for diagnosing SCID, which are now revised to incorporate contemporary approaches. Patients with typical SCID must have less than 0.05 × 109 autologous T cells/L on repetitive testing, with either pathogenic variant(s) in a SCID-associated gene, very low/undetectable T-cell receptor excision circles or less than 20% of CD4 T cells expressing naive markers, and/or transplacental maternally engrafted T cells. Patients with less profoundly impaired autologous T-cell differentiation are designated as having leaky/atypical SCID, with 2 or more of these: low T-cell numbers, oligoclonal T cells, low T-cell receptor excision circles, and less than 20% of CD4 T cells expressing naive markers. These patients must also have either pathogenic variant(s) in a SCID-associated gene or reduced T-cell proliferation to certain mitogens. Omenn syndrome requires a generalized erythematous rash, absent transplacentally acquired maternal engraftment, and 2 or more of these: eosinophilia, elevated IgE, lymphadenopathy, hepatosplenomegaly. Thymic stromal defects and other causes of secondary T-cell deficiency are excluded from the definition of SCID. Application of these revised Primary Immune Deficiency Treatment Consortium 2022 Definitions permits precise categorization of patients with T-cell defects but does not imply a preferred treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Severe Combined ImmunodeficiencyImmunologic Deficiency SyndromesHumansCD4-Positive T-LymphocytesThymus GlandReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

Omenn syndromeSCIDSevere combined immunodeficiencyleaky/atypical SCIDnewborn screeningtypical SCID

Substanzen

Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, Calif. Electronic address: christopher.dvorak@ucsf.edu.
  • Department of Pediatrics, University of Montreal, CHU Sainte-Justine, Montreal, Quebec, Canada.
  • Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, and Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pa.
  • Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, University of California San Francisco, San Francisco, Calif.
  • Division of Pediatric Allergy and Immunology, Duke University Medical Center, Durham, NC.
  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, Calif; Department of Pediatrics, University of California, Los Angeles, Los Angeles, Calif.

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NINDS NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Dvorak, C. C., Haddad, E., Heimall, J., Dunn, E., Buckley, R. H., Kohn, D. B., Cowan, M. J., Pai, S. Y., Griffith, L. M., Cuvelier, G. D. E., Eissa, H., Shah, A. J., O'Reilly, R. J., Pulsipher, M. A., Wright, N. A. M., Abraham, R. S., Satter, L. F., Notarangelo, L. D., & Puck, J. M. (2023). The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. Journal of Allergy and Clinical Immunology, 151(2), 539-546. https://doi.org/10.1016/j.jaci.2022.10.022

Vancouver

Dvorak CC, Haddad E, Heimall J, Dunn E, Buckley RH, Kohn DB, et al. The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions. Journal of Allergy and Clinical Immunology. 2023;151(2):539-546. doi:10.1016/j.jaci.2022.10.022

BibTeX
@article{Dvorak2023,
  author = {Dvorak, Christopher C and Haddad, Elie and Heimall, Jennifer and Dunn, Elizabeth and Buckley, Rebecca H and Kohn, Donald B and Cowan, Morton J and Pai, Sung-Yun and Griffith, Linda M and Cuvelier, Geoffrey D E and Eissa, Hesham and Shah, Ami J and O'Reilly, Richard J and Pulsipher, Michael A and Wright, Nicola A M and Abraham, Roshini S and Satter, Lisa Forbes and Notarangelo, Luigi D and Puck, Jennifer M},
  title = {The diagnosis of severe combined immunodeficiency (SCID): The Primary Immune Deficiency Treatment Consortium (PIDTC) 2022 Definitions},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {151},
  number = {2},
  pages = {539--546},
  doi = {10.1016/j.jaci.2022.10.022}
}
Kostenlos starten →